Do BCAAs Cause Insulin Resistance? The Evidence Says No

High-protein diets often face one metabolic accusation: they raise circulating branched-chain amino acids (BCAAs), which then cause insulin resistance. The biology sounds tidy. BCAAs—leucine, isoleucine, and valine—can activate mTOR signaling, and excessive mTOR activity can interfere with insulin signaling in cells and animals. But tidy mechanisms do not settle human causality.

Controlled human evidence points mainly in the other direction. Insulin resistance appears to impair BCAA breakdown, leaving more of these amino acids in circulation. That does not make elevated BCAAs harmless or meaningless. It means a high blood BCAA result is more likely to be a metabolic smoke alarm than proof that dietary protein started the fire.

The protein-to-insulin-resistance story failed its direct test

The most relevant dietary trial is the 2025 SPOON ancillary analysis. In this 18-month double-blind randomized trial, 84 postmenopausal women received either whey protein (38 women) or an isocaloric maltodextrin control (46 women). The researchers measured plasma BCAAs and HOMA-IR, an indirect estimate of insulin resistance.

At 18 months, the whey and carbohydrate groups did not differ in plasma BCAAs or HOMA-IR, and both measures stayed stable over the trial. That is a null result, not proof that every high-protein diet is metabolically neutral in every person. Still, it directly fails to support the claim that sustained whey supplementation predictably raises BCAAs enough to worsen insulin resistance.

The more revealing result came from the cross-sectional analysis at the end of the study. Higher plasma BCAAs tracked with higher HOMA-IR in both the protein group (p=0.03) and the maltodextrin group (p=0.02). If supplemental protein were driving the relationship, the association should have looked different between groups. Instead, it appeared regardless of which supplement participants received. The simpler explanation is that underlying metabolic health influenced both insulin resistance and circulating BCAAs.

The trial has real limits. It enrolled mostly White postmenopausal women, excluded people with BMI above 32 kg/m², and used HOMA-IR rather than a hyperinsulinemic-euglycemic clamp. It therefore cannot settle the question for younger adults, people with obesity, or patients with type 2 diabetes. But it is stronger evidence about dietary protein than a one-time blood test paired with a food questionnaire.

Insulin resistance improved while BCAAs stayed high

A second intervention asks a different but useful question: must BCAAs fall for insulin resistance to improve? In a 2022 caloric-restriction study, 10 obese men followed a very-low-calorie diet of about 600 kcal per day for six weeks. Glycemic control and HOMA-IR improved, yet plasma BCAAs and branched-chain keto acids (BCKAs) did not decrease.

This study does not prove that BCAAs never contribute to insulin resistance. It was small, single-arm, short, and had no randomized comparator. Its value is narrower: BCAA normalization was not necessary for improved glycemic control in these men. That finding weakens a model in which high circulating BCAAs must sit upstream of—and maintain—insulin resistance.

Exercise data fit the same broad pattern. In sedentary dysglycemic and normoglycemic men, an exercise-training study found that improvements in insulin sensitivity occurred alongside changes in BCAA metabolism. Co-movement cannot establish which change came first, but it is consistent with recovery of metabolic capacity improving BCAA handling.

Genetics support reverse causation, with one important exception

Observational studies cannot easily untangle cause from consequence. Mendelian randomization tries to address that problem by using genetic variants associated with an exposure as proxies for lifelong differences in that exposure. In a 2025 bidirectional Mendelian-randomization study of 272,281 UK Biobank participants, genetic liability to insulin resistance increased circulating BCAAs. The reverse analysis did not support BCAAs as a cause of type 2 diabetes or obesity.

That result favors the reverse-arrow model: metabolic dysfunction raises BCAAs. Yet the study also found a forward genetic signal linking higher BCAAs to dyslipidemia, specifically higher triglycerides and lower HDL cholesterol. This is the important exception. BCAAs may not be a primary dietary cause of insulin resistance, but chronically high BCAAs could still worsen lipid metabolism or reflect a pathway that does.

Mendelian randomization is not a randomized trial. Its genetic instruments can have effects through more than one biological route, the cohort had predominantly White European ancestry, and participants fasted for only about four hours on average. The dyslipidemia signal needs replication. Still, the study is difficult to reconcile with sweeping claims that dietary BCAAs cause diabetes or obesity.

Why BCAAs accumulate

BCAAs are not simply dietary leftovers. The body must break them down, and impaired flux through the branched-chain ketoacid dehydrogenase (BCKDH) pathway can leave BCAAs and their downstream metabolites elevated. A 2025 adipocyte cell-culture study found that disrupting BCAA catabolism during fat-cell differentiation reduced glycolytic flux. That supports the idea that adipose BCAA handling matters for metabolic function, but cells in a dish cannot establish what causes insulin resistance in humans.

Downstream metabolites may also matter more than the parent amino acids alone. In a cross-sectional study of obese adolescents, BCKAs and glutamate/glutamine were higher in insulin-resistant than insulin-sensitive participants, with some sex-dependent associations. Because the study measured one point in time and focused on a pediatric population, it cannot identify cause or generalize cleanly to adults. It does, however, argue against treating "BCAAs" as one simple molecule with one simple effect.

A separate cross-sectional analysis of 403 non-diabetic adults found insulin resistance associated with patterns of amino acids and acylcarnitines, including BCAA-pathway metabolites (Arjmand et al., 2022). Such biomarker patterns can help identify impaired metabolism. They do not tell us whether restricting steak, whey, or leucine will fix it.

The strongest counterargument is narrower than the popular claim

The proposed BCAA-to-insulin-resistance mechanism remains biologically plausible. A 2026 review describes evidence that excessive BCAA signaling may activate mTOR, increase inhibitory serine phosphorylation of IRS-1, and reduce insulin signaling. The review also discusses a small human study of sodium phenylbutyrate in 16 participants, in which enhancing BCAA disposal improved insulin sensitivity by about 27%.

That result deserves attention, but it does not settle the dietary question. The intervention was small, has not been established as BCAA-specific, and sodium phenylbutyrate affects more than BCAA catabolism. It supports the possibility that altered BCAA metabolism can contribute to disease in some settings. It does not show that eating more protein or taking BCAA supplements causes insulin resistance in metabolically healthy people.

Elevated BCAAs look more like a clue to impaired metabolic handling than a blanket indictment of protein intake.

What to do with a high BCAA result

For a metabolically healthy person, current controlled evidence does not justify restricting protein or BCAA-containing foods solely to prevent insulin resistance. The SPOON trial found no worsening with long-term whey supplementation, while a small 60-day bed-rest randomized trial found that a high-protein diet providing 1.45 g/kg/day protein plus 0.15 g/kg/day supplemental BCAAs prevented inactivity-induced insulin resistance in healthy women. In the conventional-diet group, insulin-mediated glucose uptake fell from 155±23% to 84±10% (p=0.01); it remained unchanged in the high-protein group, moving from 126±20% to 141±27% (diet-by-bed-rest interaction p=0.01) (Mangogna et al., 2023).

That bed-rest study included only eight women per group and modeled an extreme form of inactivity, so it cannot prescribe a diet for people with established metabolic disease. Its result does show that BCAA enrichment did not automatically impair insulin action under controlled physiological stress.

If BCAAs are elevated alongside insulin resistance, focus on the condition with established clinical targets: physical activity, energy balance, glycemic control, triglycerides, HDL cholesterol, and treatment plans tailored with a clinician. Check the lipid panel rather than treating a BCAA value as a dietary conviction. The current human evidence supports fixing impaired metabolism first; lower BCAAs may follow, but they need not lead.